192 research outputs found
CD4 memory T cells divide poorly in response to antigen because of their cytokine profile
Immunological memory is a hallmark of adaptive immunity, and understanding T cell memory will be central to the development of effective cell-mediated vaccines. The characteristics and functions of CD4 memory cells have not been well defined. Here we demonstrate that the increased size of the secondary response is solely a consequence of the increased antigen-specific precursor frequency within the memory pool. Memory cells proliferated less than primary responding cells, even within the same host. By analyzing the entry of primary and memory cells into the cell cycle, we found that the two populations proliferated similarly until day 5; after this time, fewer of the reactivated memory cells proliferated. At this time, fewer of the reactivated memory cells made IL-2 than primary responding cells, but more made IFNγ. Both these factors affected the low proliferation of the memory cells, because either exogenous IL-2 or inhibition of IFNγ increased the proliferation of the memory cells
Interdisziplinarität bei seltenen Krankheiten diskutiert anhand des kyphoskoliotischen Ehlers-Danlos-Syndroms
Dynamics of Relativistic Interacting Gases : from a Kinetic to a Fluid Description
Starting from a microscopic approach, we develop a covariant formalism to
describe a set of interacting gases. For that purpose, we model the collision
term entering the Boltzmann equation for a class of interactions and then
integrate this equation to obtain an effective macroscopic description. This
formalism will be useful to study the cosmic microwave background
non-perturbatively in inhomogeneous cosmologies. It should also be useful for
the study of the dynamics of the early universe and can be applied, if one
considers fluids of galaxies, to the study of structure formation.Comment: Latex file, 28 pages, accepted for publication in Class. Quant. Gra
Swiss Adult Congenital HEart disease Registry (SACHER) - rationale, design and first results.
In 2013, a prospective registry for adults with congenital heart disease (CHD) was established in Switzerland, providing detailed data on disease characteristics and outcomes: Swiss Adult Congenital HEart disease Registry (SACHER). Its aim is to improve the knowledge base of outcomes in adults with CHD. The registry design and baseline patient characteristics are reported.
All patients with structural congenital heart defects or hereditary aortopathies, followed-up at dedicated adult CHD clinics, are asked to participate in SACHER. Data of participants are pseudonymised and collected in an electronic, web-based, database (secuTrial®). Collected data include detailed diagnosis, type of repair procedures, previous complications and adverse outcomes during follow-up.
From May 2014 to December 2016, 2836 patients (54% male, mean age 34 ± 14 years), with a wide variety of congenital heart lesions, have been enrolled into SACHER. Most prevalent were valve lesions (25%), followed by shunt lesions (22%), cyanotic and other complex congenital heart disease (16%), diseases affecting the right heart, i.e., tetralogy of Fallot or Ebstein anomaly (15%), and diseases of the left ventricular outflow tract (13%); 337 patients (12%) had concomitant congenital syndromes. The majority had undergone previous repair procedures (71%), 47% of those had one or more reinterventions.
SACHER collects multicentre data on adults with CHD. Its structure enables prospective data analysis to assess detailed, lesion-specific outcomes with the aim to finally improve long-term outcomes
CD40-CD40 ligand interactions are critical in T-B cooperation but not for other anti-viral CD4+ T cell functions.
The CD8 T cell coreceptor exhibits disproportionate biological activity at extremely low binding affinities
Immune control of HIV-1 infection after therapy interruption: immediate versus deferred antiretroviral therapy
Abstract Background The optimal stage for initiating antiretroviral therapies in HIV-1 bearing patients is still a matter of debate. Methods We present computer simulations of HIV-1 infection aimed at identifying the pro et contra of immediate as compared to deferred Highly Active Antiretroviral Therapy (HAART). Results Our simulations highlight that a prompt specific CD8+ cytotoxic T lymphocytes response is detected when therapy is delayed. Compared to very early initiation of HAART, in deferred treated patients CD8+ T cells manage to mediate the decline of viremia in a shorter time and, at interruption of therapy, the virus experiences a stronger immune pressure. We also observe, however, that the immunological effects of the therapy fade with time in both therapeutic regimens. Thus, within one year from discontinuation, viral burden recovers to the value at which it would level off in the absence of therapy. In summary, simulations show that immediate therapy does not prolong the disease-free period and does not confer a survival benefit when compared to treatment started during the chronic infection phase. Conclusion Our conclusion is that, since there is no therapy to date that guarantees life-long protection, deferral of therapy should be preferred in order to minimize the risk of adverse effects, the occurrence of drug resistances and the costs of treatment.</p
In Vivo CD8+ T-Cell Suppression of SIV Viremia Is Not Mediated by CTL Clearance of Productively Infected Cells
The CD8+ T-cell is a key mediator of antiviral immunity, potentially contributing to control of pathogenic lentiviral infection through both innate and adaptive mechanisms. We studied viral dynamics during antiretroviral treatment of simian immunodeficiency virus (SIV) infected rhesus macaques following CD8+ T-cell depletion to test the importance of adaptive cytotoxic effects in clearance of cells productively infected with SIV. As previously described, plasma viral load (VL) increased following CD8+ T-cell depletion and was proportional to the magnitude of CD8+ T-cell depletion in the GALT, confirming a direct relationship between CD8+ T-cell loss and viral replication. Surprisingly, first phase plasma virus decay following administration of antiretroviral drugs was not slower in CD8+ T-cell depleted animals compared with controls indicating that the short lifespan of the average productively infected cell is not a reflection of cytotoxic T-lymphocyte (CTL) killing. Our findings support a dominant role for non-cytotoxic effects of CD8+ T-cells on control of pathogenic lentiviral infection and suggest that cytotoxic effects, if present, are limited to early, pre-productive stages of the viral life cycle. These observations have important implications for future strategies to augment immune control of HIV
Identification of HIV-1 Epitopes that Induce the Synthesis of a R5 HIV-1 Suppression Factor by Human CD4+ T Cells Isolated from HIV-1 Immunized Hu-PBL SCID Mice
We have previously reported that immunization of the severe combined
immunodeficiency (SCID) mice reconstituted with human peripheral blood
mononuclear cells (PBMC) (hu-PBL-SCID mice) with inactivated human
immunodeficiency virus type-1 (HIV-1)-pulsed-autologous dendritic cells (HIV-DC)
elicits HIV-1-reactive CD4+ T cells that produce an as yet to be defined novel
soluble factor in vitro with anti-viral properties
against CCR5 tropic (R5) HIV-1
infection. These findings led us to perform studies designed to identify the lineage
of the cell that synthesizes such a factor in vitro and define the epitopes of HIV-1
protein that have specificity for the induction of such anti-viral factor. Results of
our
studies show that this property is a function of CD4+ but not
CD8+ T cells. Human
CD4+ T cells were thus recovered from the HIV-DC-immunized
hu-PBL-SCID mice
and were re-stimulated in vitro by co-culture for 2 days with
autologous adherent
PBMC as antigen presenting cells, APC previously pulsed with inactivated HIV in
IL-2-containing medium to expand HIV-1-reactive CD4+
T cells. Aliquots of these
re-stimulated CD4+ T cells were then co-cultured with
similar APC's that were
previously pulsed with 10 μg/ml of a panel of HIV peptides for
an additional 2 days,
and their culture supernatants were examined for the production of both the R5
HIV-1 suppression factor and IFN-Υ. The data presented herein
show that the HIV-1
primed CD4+ T cells produced the R5 suppression factor in
response to a wide
variety of HIV-1 gag, env, pol, nef or vif peptides, depending on the donor of
the CD4+ T cells. Simultaneous production of human interferon
(IFN)-Υ was
observed in some cases. These results indicate that human
CD4+ T cells in
PBMC of HIV-1 naive donors have a wide variety of HIV-1 epitope-specific
CD4+ T
cell precursors that are capable of producing the R5 HIV-1
suppression factor upon DC-based vaccination with whole inactivated HIV-1
Cellular Immune Responses and Viral Diversity in Individuals Treated during Acute and Early HIV-1 Infection
Immune responses induced during the early stages of chronic viral infections are thought to influence disease outcome. Using HIV as a model, we examined virus-specific cytotoxic T lymphocytes (CTLs), T helper cells, and viral genetic diversity in relation to duration of infection and subsequent response to antiviral therapy. Individuals with acute HIV-1 infection treated before seroconversion had weaker CTL responses directed at fewer epitopes than persons who were treated after seroconversion. However, treatment-induced control of viremia was associated with the development of strong T helper cell responses in both groups. After 1 yr of antiviral treatment initiated in acute or early infection, all epitope-specific CTL responses persisted despite undetectable viral loads. The breadth and magnitude of CTL responses remained significantly less in treated acute infection than in treated chronic infection, but viral diversity was also significantly less with immediate therapy. We conclude that early treatment of acute HIV infection leads to a more narrowly directed CTL response, stronger T helper cell responses, and a less diverse virus population. Given the need for T helper cells to maintain effective CTL responses and the ability of virus diversification to accommodate immune escape, we hypothesize that early therapy of primary infection may be beneficial despite induction of less robust CTL responses. These data also provide rationale for therapeutic immunization aimed at broadening CTL responses in treated primary HIV infection
- …